China Pharma Revenue, Profits - CPHI Annual Income Statement

Add to My Stocks
$0.23 $0 (0%) CPHI stock closing price Jun 21, 2018 (Closing)

Fundamental analysis of CPHI stock involves analyzing its financial statements, apart from checking the China Pharma stock price. The income statement gives the investor an understanding of the topline or revenue and bottomline or profit numbers of the company and helps investors evaluate if a company has been growing or not. The income statement for CPHI which shows a YOY revenue decline of -15.16% is specific to a period of time. Investors typically check YoY or QoQ revenue growth. The China Pharma profit and loss statement for 2017 shows a net profit of $-19.27M. Profits for last year was $-9.18M. Apart from this an investor should also check China Pharma assets and China Pharma free cash flow.

View revenue and profit details for latest and last 10 financial years.
show more
Quarterly
Annual
View Previous Years
View Next Years
Fiscal year is Jan - Dec2017201620152014201320122011201020092008
China Pharma Revenues or Net Sales
13.21M15.57M20.35M24.92M32.8M54.5M81.16M74.38M61.69M50.96M
Cost Of Goods Sold (COGS)10.74M12.35M18.88M19.46M33.28M40.43M52.17M44.1M36.04M25.67M
China Pharma Gross Profit
2.46M3.21M1.46M5.46M-0.48M14.07M28.98M30.28M25.65M25.29M
Research & Development Expense---2.79M1.68M-----
Selling General & Admin Expense21.05M11M14.8M27.91M16.44M8.31M7.26M6.08M3.03M5.56M
Income Before Depreciation Depletion Amortization-18.68M-8.15M-14.29M-25.25M-18.6M5.76M21.72M24.19M22.61M19.73M
Depreciation Depletion Amortization----------
Non Operating Income------1.24M2.07M--0.05M
Interest Expense--1.16M-------
China Pharma Pretax Income
-19.15M-8.87M-15.34M-25.97M-18.94M5.6M22.71M26.1M22.49M19.54M
Provision for Income Taxes----1.06M-3.44M2.68M2.26M1.7M
MinorityInterest----------
Investment Gains Losses----------
Other Income----------
Income Before Extraordinaries & Disc Operations-19.27M-9.18M-15.4M-26.04M-20M4.61M19.26M23.41M20.23M17.83M
Extraordinary Items & Discontinued Operations----------
China Pharma Profit/ Loss (Net Income)
-19.27M-9.18M-15.4M-26.04M-20M4.61M19.26M23.41M20.23M17.83M
Average Shares used to compute Diluted EPS43.58M43.58M44.02M43.41M43.5M41.98M43.8M43.36M42.15M40.22M
Average Shares used to compute Basic EPS43.58M43.58M44.02M43.41M43.5M41.98M43.8M43.36M42.15M40.22M
Income Before Nonrecurring Items-19.28M-9.18M-15.34M-26.05M-20.01M5M18.66M21.83M20.23M17.83M
Income from Nonrecurring Items---0.07M---0.39M-1.59M--
China Pharma Earnings Per Share Basic Net
-0.44-0.21-0.35-0.60-0.460.110.440.540.480.44
China Pharma Earnings Per Share Diluted Net
-0.44-0.21-0.35-0.60-0.460.110.440.540.480.44
EPS Diluted Before Nonrecurring Items-0.44-0.21-0.35-0.60-0.460.120.430.500.480.44
Preferred Dividends Acc Pd----------
Dividends Common----------
Dividend Per Share Common0.000.000.000.000.000.000.000.000.000.00
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Years
View Next Years

Click here to view our Mylan financial analysis

It is very helpful to read a report on China Pharma stock analysis. An investor must check the following items in an income statement:

  • Topline: A growing topline, as seen from the China Pharma revenue chart, as isn't the case with China Pharma indicates a sagging business. One needs to compare the YoY topline or sales growth of CPHI stock with its peers like AGRX stock and ACST stock to see if the growth compares well with what can be expected from a company in that industry.
  • Bottom line: Most businesses like China Pharma try to grow their profits by growing their topline and by increasing their operating efficiency. A healthy bottom line growth implies a good investment.

The income statement is also called the profit and loss statement. Apart from the CPHI income statement, one can check the China Pharma historical stock prices to check how the price has moved with time.

China Pharma Income Statement - Key Financial Ratios

PS Ratio (price sales ratio)
0.74
Dividend Yield
0%